Aspegic ® (Aspirin) — Competitive Intelligence Brief

Aspegic ® (Aspirin) (Aspegic ® (Aspirin)) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent. Area: Cardiovascular; Pain management; Inflammation.

phase 3 Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2) Cardiovascular; Pain management; Inflammation Small molecule

Target snapshot

Aspegic ® (Aspirin) (Aspegic ® (Aspirin)) — Assistance Publique - Hôpitaux de Paris. Aspirin irreversibly inhibits cyclooxygenase (COX) enzymes, reducing the production of prostaglandins and thromboxane to decrease inflammation, pain, and platelet aggregation.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Aspegic ® (Aspirin) TARGET	Aspegic ® (Aspirin)	Assistance Publique - Hôpitaux de Paris	phase 3	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)
Aspirin loading dose	Aspirin loading dose	Icahn School of Medicine at Mount Sinai	marketed	Antiplatelet agent; nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)
Novel strategy Aspirin	Novel strategy Aspirin	Assistance Publique - Hôpitaux de Paris	marketed	Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent	Cyclooxygenase-1 (COX-1); Cyclooxygenase-2 (COX-2)
Active ASA	Active ASA	Hamilton Health Sciences Corporation	marketed	Nonsteroidal Anti-Inflammatory Drug (NSAID)	Cyclooxygenase (COX) enzymes
Diclofenac oral + Placebo Oral	Diclofenac oral + Placebo Oral	Hospital de Clinicas de Porto Alegre	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-1 and COX-2
ketorolac (Acular LS)	ketorolac (Acular LS)	Center For Excellence In Eye Care	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	Cyclooxygenase (COX-1 and COX-2)
Nerkardou (5 mg) & (10 mg)	Nerkardou (5 mg) & (10 mg)	Genuine Research Center, Egypt	marketed	Nonsteroidal anti-inflammatory drug (NSAID)	COX-2

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Nonsteroidal anti-inflammatory drug (NSAID); antiplatelet agent class)

1. Assistance Publique - Hôpitaux de Paris · 3 drugs in this class
2. Basque Health Service · 2 drugs in this class
3. PLx Pharma · 2 drugs in this class
4. Biogen · 1 drug in this class
5. Eli Lilly and Company · 1 drug in this class
6. Harbin Medical University · 1 drug in this class
7. Janssen Scientific Affairs, LLC · 1 drug in this class
8. Azienda Ospedaliera San Giovanni Battista · 1 drug in this class
9. Royal College of Surgeons, Ireland · 1 drug in this class
10. Shiraz University of Medical Sciences · 1 drug in this class